SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Stock Holdings Lifted by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. lifted its position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 40.2% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 13,568 shares of the company’s stock after acquiring an additional 3,892 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in SpringWorks Therapeutics were worth $511,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SWTX. Charles Schwab Investment Management Inc. lifted its holdings in shares of SpringWorks Therapeutics by 18.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 501,067 shares of the company’s stock valued at $18,289,000 after purchasing an additional 77,303 shares in the last quarter. Teacher Retirement System of Texas raised its position in SpringWorks Therapeutics by 5.1% during the fourth quarter. Teacher Retirement System of Texas now owns 10,268 shares of the company’s stock valued at $375,000 after buying an additional 498 shares during the period. Principal Financial Group Inc. lifted its stake in SpringWorks Therapeutics by 8.3% in the 4th quarter. Principal Financial Group Inc. now owns 16,120 shares of the company’s stock worth $588,000 after acquiring an additional 1,231 shares in the last quarter. Norges Bank acquired a new stake in SpringWorks Therapeutics during the 4th quarter worth about $12,331,000. Finally, Assetmark Inc. grew its stake in SpringWorks Therapeutics by 48.8% during the 4th quarter. Assetmark Inc. now owns 16,090 shares of the company’s stock valued at $587,000 after acquiring an additional 5,276 shares in the last quarter.

Analyst Upgrades and Downgrades

SWTX has been the subject of several research reports. Wedbush restated an “outperform” rating and set a $77.00 price target (up from $75.00) on shares of SpringWorks Therapeutics in a report on Wednesday, August 28th. JPMorgan Chase & Co. boosted their price target on shares of SpringWorks Therapeutics from $64.00 to $68.00 and gave the company an “overweight” rating in a report on Wednesday, September 4th. Finally, HC Wainwright reiterated a “buy” rating and set a $76.00 price objective on shares of SpringWorks Therapeutics in a report on Wednesday, August 28th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $68.50.

SpringWorks Therapeutics Trading Down 2.7 %

SpringWorks Therapeutics stock opened at $34.38 on Friday. The company has a market capitalization of $2.55 billion, a P/E ratio of -6.69 and a beta of 0.79. SpringWorks Therapeutics, Inc. has a 1-year low of $18.00 and a 1-year high of $53.92. The firm’s fifty day simple moving average is $37.80 and its 200-day simple moving average is $41.38.

SpringWorks Therapeutics (NASDAQ:SWTX) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.58. The company had revenue of $59.73 million during the quarter, compared to analyst estimates of $34.42 million. SpringWorks Therapeutics’s quarterly revenue was up 59732900.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.25) EPS. On average, equities research analysts predict that SpringWorks Therapeutics, Inc. will post -3.36 earnings per share for the current year.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.